Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Nasdaq Copenhagen  -  05/18 10:59:36 am EDT
742.90 DKK   -0.79%
05/16European ADRs Move Higher in Monday Trading
MT
05/16NOVO NORDISK A/S : Share repurchase programme
GL
05/16NOVO NORDISK A/S : Share repurchase programme
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
05/11/2022 05/12/2022 05/16/2022 05/17/2022 05/18/2022 Date
747(c) 749.1(c) 735(c) 748.8(c) 742.9(c) Last
2 262 278 1 665 266 2 578 383 1 380 848 1 387 187 Volume
-1.75% +0.28% -1.88% +1.88% -0.79% Change
More quotes
Estimated financial data (e)
Sales 2022 166 B 23 416 M 23 416 M
Net income 2022 52 794 M 7 449 M 7 449 M
Net cash position 2022 4 087 M 577 M 577 M
P/E ratio 2022 31,7x
Yield 2022 1,54%
Sales 2023 187 B 26 427 M 26 427 M
Net income 2023 63 100 M 8 903 M 8 903 M
Net cash position 2023 9 504 M 1 341 M 1 341 M
P/E ratio 2023 26,2x
Yield 2023 1,80%
Capitalization 1 687 B 238 B 238 B
EV / Sales 2022 10,1x
EV / Sales 2023 8,96x
Nbr of Employees 49 295
Free-Float 69,6%
More Financials
Company
Novo Nordisk A/S specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (86.4%); - hemophilia treatment products (7.3%): mainly injections of protein; - growth hormones (5.1%): used for treatment of growth deficiencies in children; - hormone replacement products (1.2%): used for treatment... 
Read more
Sector
Pharmaceuticals
Calendar
05/23Presentation
More about the company
Ratings of Novo Nordisk A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A
More Ratings
All news about NOVO NORDISK A/S
05/16European ADRs Move Higher in Monday Trading
MT
05/16NOVO NORDISK A/S : Share repurchase programme
GL
05/16NOVO NORDISK A/S : Share repurchase programme
GL
05/13U.S. FDA approves Eli Lilly's treatment for type 2 diabetes
RE
05/12NOVO NORDISK : Barclays gives a Buy rating
MD
05/11NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associa..
GL
05/11NOVO NORDISK : Deutsche Bank keeps its Buy rating
MD
05/10Novo Nordisk Starts Research Collaboration With Flagship Pioneering
MT
05/09Novo Nordisk - major shareholder announcement
AQ
05/06NOVO NORDISK A/S :
GL
05/06NOVO NORDISK A/S :
GL
05/06NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associa..
GL
05/05Bryan Garnier Upgrades Novo Nordisk to Neutral From Sell
MT
05/05TRANSCRIPT : Novo Nordisk A/S, Q1 2022 Earnings Call, May 05, 2022
CI
05/05NOVO NORDISK : Buy rating from Bernstein
MD
More news
News in other languages on NOVO NORDISK A/S
05/16Les ADR européens progressent lundi
05/10NOVO NORDISK : collaboration avec Flagship Pioneering
05/10Novo Nordisk entame une collaboration de recherche avec un pionnier de l'industrie phar..
05/10BIOCORP : Interview de Eric Dessertenne, Directeur général de Biocorp
05/09LA VALEUR DU JOUR À PARIS - ADOCIA : lancement d'une phase 3 avec l'insuline ultra-rapide ..
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Stock Trading Strategies
NOVO NORDISK A/S - 03/08
Good timing to anticipate a continuation of the trend
BUY
More Stock Trading Analysis
Analysis
Novo Nordisk lifts 2022 outlook after strong quarter, shares jump
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 742,90 DKK
Average target price 791,88 DKK
Spread / Average Target 6,59%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S1.88%240 809
JOHNSON & JOHNSON4.53%470 547
PFIZER, INC.-13.06%288 063
ABBVIE INC.14.31%273 513
ELI LILLY AND COMPANY9.12%271 308
ROCHE HOLDING AG-14.97%263 868